Therapeutic consequences of pathology and prognostic factors in aggressive NHL--analysis of ALCL.
Gascoyne
R D
RD
Department of Pathology, British Columbia Cancer Agency. rgascoyne@bccancer.bc.ca
D030201:Activin Receptors, Type I / Q000032:analysis / Q000235:genetics / Q000502:physiology; D030301:Activin Receptors, Type II; D014408:Biomarkers, Tumor / Q000235:genetics / Q000502:physiology; D006801:Humans; D016130:Immunophenotyping; D017730:Ki-1 Antigen / Q000032:analysis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000502:physiology; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen; C107023:p80(NPM-ALK) protein; D011505:Protein-Tyrosine Kinases; C425364:ACVRL1 protein, human; D030201:Activin Receptors, Type I; D030301:Activin Receptors, Type II